Wedbush Reiterates Outperform on Astria Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Astria Therapeutics (NASDAQ:ATXS) and maintained a $22 price target.
August 13, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico has reiterated an Outperform rating on Astria Therapeutics and maintained a $22 price target.
The reiteration of an Outperform rating and the maintenance of a $22 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100